Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-041379
Filing Date
2025-03-18
Accepted
2025-03-18 17:03:49
Documents
73
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K inkt-20241231.htm   iXBRL 10-K 2179588
2 EX-19.1 inkt-ex19_1.htm EX-19.1 117214
3 EX-21.1 inkt-ex21_1.htm EX-21.1 7241
4 EX-23.1 inkt-ex23_1.htm EX-23.1 3520
5 EX-31.1 inkt-ex31_1.htm EX-31.1 16860
6 EX-31.2 inkt-ex31_2.htm EX-31.2 16831
7 EX-32.1 inkt-ex32_1.htm EX-32.1 9643
8 EX-32.2 inkt-ex32_2.htm EX-32.2 9606
9 GRAPHIC img207893214_0.jpg GRAPHIC 47928
  Complete submission text file 0000950170-25-041379.txt   7806963

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inkt-20241231.xsd EX-101.SCH 1116876
76 EXTRACTED XBRL INSTANCE DOCUMENT inkt-20241231_htm.xml XML 948469
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40908 | Film No.: 25749361
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)